Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 75, Issue 6, Pages 1065-1073
Publisher
BMJ
Online
2016-01-21
DOI
10.1136/annrheumdis-2015-207963
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
- (2015) C. Paul et al. BRITISH JOURNAL OF DERMATOLOGY
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study
- (2013) Vibeke Strand et al. Health and Quality of Life Outcomes
- Effect of Enthesitis on 1505 Brazilian Patients with Spondyloarthritis
- (2013) S. Carneiro et al. JOURNAL OF RHEUMATOLOGY
- Enthesitis in psoriatic arthritis
- (2013) Lazaros I. Sakkas et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
- (2012) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
- (2012) Georg Schett et al. ARTHRITIS AND RHEUMATISM
- Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
- (2012) Peter Schafer BIOCHEMICAL PHARMACOLOGY
- A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
- (2012) Gabrielle H. Kingsley et al. RHEUMATOLOGY
- A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis
- (2011) Zoe Ash et al. ANNALS OF THE RHEUMATIC DISEASES
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2011) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2009) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More